ArcticZymes Technologies ASA
LSE:0DRV Lagerbericht
Marktkapitalisierung: NOK 710.9m
ArcticZymes Technologies Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6 ArcticZymes Technologies hat ein Gesamteigenkapital von NOK318.8M und eine Gesamtverschuldung von NOK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen NOK341.8M bzw. NOK22.9M.
Wichtige Informationen
0%
Verhältnis von Schulden zu Eigenkapital
Zinsdeckungsgrad n/a Bargeld NOK 242.12m Eigenkapital NOK 318.82m Gesamtverbindlichkeiten NOK 22.93m Gesamtvermögen NOK 341.75m
Jüngste Berichte zur Finanzlage
Alle Updates anzeigen
Chief Executive Officer recently bought kr102k worth of stock Nov 10
New minor risk - Profit margin trend Nov 07
Investor sentiment deteriorates as stock falls 16% Nov 06
Investor sentiment deteriorates as stock falls 17% Sep 05
New major risk - Earnings quality Aug 26
Second quarter 2024 earnings released: EPS: kr0.05 (vs kr0.11 in 2Q 2023) Aug 23
Investor sentiment improves as stock rises 15% Jul 31
ArcticZymes Technologies ASA Announces the Appointment of Frank Mathias as Chairman of the Board of Directors Jul 31
New major risk - Earnings quality May 17
Less than half of directors are independent May 15
ArcticZymes Technologies ASA Announces Board Resignations May 14
ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board Member Apr 02
Investor sentiment deteriorates as stock falls 15% Feb 15
New minor risk - Share price stability Feb 10
New major risk - Earnings quality Feb 07
Full year 2023 earnings released: EPS: kr0.37 (vs kr0.65 in FY 2022) Feb 02
Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San Hq Jan 30
ArcticZymes Technologies ASA Launches T7 RNA Polymerase Dec 21 ArcticZymes Technologies ASA, Annual General Meeting, Jun 05, 2024
New minor risk - Share price stability Nov 03
Third quarter 2023 earnings released: EPS: kr0.12 (vs kr0.05 in 3Q 2022) Nov 03
ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA Sep 21
Second quarter 2023 earnings released: EPS: kr0.11 (vs kr0.17 in 2Q 2022) Aug 18
ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023 Jul 17
First quarter 2023 earnings released: EPS: kr0.10 (vs kr0.41 in 1Q 2022) May 05
Director recently bought kr426k worth of stock Feb 05
Full year 2022 earnings released: EPS: kr0.65 (vs kr0.94 in FY 2021) Feb 04
Investor sentiment deteriorated over the past week Jan 05
ArcticZymes Technologies Launches SAN HQ 2.0 ELISA kit Dec 21
ArcticZymes Technologies ASA Appoints Darren Ellis as Chief Scientific Officer Dec 02 ArcticZymes Technologies ASA to Report Q4, 2022 Results on Feb 02, 2023
No independent directors Nov 16
Third quarter 2022 earnings released: EPS: kr0.05 (vs kr0.14 in 3Q 2021) Oct 28
ArcticZymes Technologies ASA Announces Resignation of Volker Wedershoven as Board Member Oct 25
Second quarter 2022 earnings released: EPS: kr0.17 (vs kr0.09 in 2Q 2021) Aug 19
Director recently sold kr169k worth of stock Jul 06
First quarter 2022 earnings released: EPS: kr0.41 (vs kr0.40 in 1Q 2021) Apr 29
No independent directors Apr 27
ArcticZymes Technologies ASA Provides Sales Guidance for the Year 2022 Jan 28
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Jan 28
ArcticZymes Technologies Launches New Products Dec 22
Chief Executive Officer recently sold kr11m worth of stock Dec 12
Third quarter 2021 earnings released: EPS kr0.14 (vs kr0.19 in 3Q 2020) Oct 30
Second quarter 2021 earnings released: EPS kr0.09 (vs kr0.44 in 2Q 2020) Aug 22
Investor sentiment deteriorated over the past week Aug 19
ArcticZymes Technologies ASA Launches SAN HQ 2.0 Jun 30
Director recently sold kr1.7m worth of stock May 20
Investor sentiment improved over the past week Apr 29
First quarter 2021 earnings released: EPS kr0.40 (vs kr0.19 in 1Q 2020) Apr 25
Full year 2020 earnings released: EPS kr1.75 (vs kr0.13 loss in FY 2019) Jan 30
ArcticZymes Technologies ASA to Report Q4, 2020 Results on Jan 28, 2021 Jan 26
Market pulls back on stock over the past week Nov 20
Market pulls back on stock over the past week Nov 13
ArcticZymes Technologies ASA to Report Q3, 2020 Results on Oct 22, 2020 Sep 23
ArcticZymes Technologies ASA to Report Q2, 2020 Results on Aug 19, 2020 Aug 14
Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: 0DRVDie kurzfristigen Aktiva des Unternehmens (NOK280.5M) übersteigen seine kurzfristigen Passiva (NOK17.7M).
Langfristige Verbindlichkeiten: 0DRVDie kurzfristigen Vermögenswerte des Unternehmens (NOK280.5M) übersteigen seine langfristigen Verbindlichkeiten (NOK5.2M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: 0DRV ist schuldenfrei.
Schulden abbauen: 0DRV hat in den letzten 5 Jahren keine Schulden gemacht.
Schuldendeckung: 0DRV hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.
Zinsdeckung: 0DRV hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.
Entdecken Sie finanziell stabile Unternehmen Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}